Literature DB >> 21207062

Prevalence of molecular markers of Plasmodium falciparum resistance to sulfadoxine-pyrimethamine during the intermittent preventive treatment in infants coupled with the expanded program immunization in Senegal.

Babacar Faye1, Magatte Ndiaye, Jean Louis Ndiaye, Abiola Annie, Roger Clement Tine, Aminata Collé Lo, Mohamed Ndiaye, Doudou Sow, Alexandra De Sousa, Oumar Gaye.   

Abstract

Several studies have shown the efficacy of the intermittent preventive treatment (IPT) using sulfadoxine-pyrimethamine (SP) coupled with the expanded program of immunization (EPI) in infants. However, its adoption as a strategy is conditioned by the long-term efficacy of SP. The impact of IPT-SP coupled with the EPI on the prevalence of markers of resistance to SP was evaluated during this study conducted in Southern Senegal. Three cross-sectional surveys in two health districts (IPT+) were conducted prior to the implementation, 1 year, and 2 years after. A third district located between the two districts served as a test zone (IPT-). PCR tests were carried out from filter papers collected in children under five for the two first measures and from positive rapid diagnostic tests in the same population for the third measure. Mutations in codons 51, 59, and 108 of the DHFR gene and in codons 437 and 540 of the DHPS were analyzed. The results showed that the prevalence of DHFR triple mutation was more frequent after 2 years in IPT+ areas. Regarding quadruple mutation, DHFR (51, 59, and 108) and DHPS (437), no difference was noted between the two areas. The quintuple mutation was not observed after 2 years of implementation in both areas. However, an individual analysis showed significant differences in the individual mutation points 51, 59, 108, and 437. This study reveals that despite an increase in the prevalence of individual mutations, the IPT-SP coupled with the EPI has no major impact on DHFR and DHPS combined mutations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21207062     DOI: 10.1007/s00436-010-2236-9

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  21 in total

1.  Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria.

Authors:  James G Kublin; Fraction K Dzinjalamala; Deborah D Kamwendo; Elissa M Malkin; Joseph F Cortese; Lisa M Martino; Rabia A G Mukadam; Stephen J Rogerson; Andres G Lescano; Malcolm E Molyneux; Peter A Winstanley; Phillips Chimpeni; Terrie E Taylor; Christopher V Plowe
Journal:  J Infect Dis       Date:  2002-01-17       Impact factor: 5.226

2.  Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: a randomized, placebo-controlled trial.

Authors:  Eusebio Macete; Pedro Aide; John J Aponte; Sergi Sanz; Inacio Mandomando; Mateu Espasa; Betuel Sigauque; Carlota Dobaño; Samuel Mabunda; Martinho DgeDge; Pedro Alonso; Clara Menendez
Journal:  J Infect Dis       Date:  2006-06-30       Impact factor: 5.226

3.  Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.

Authors:  D Schellenberg; C Menendez; E Kahigwa; J Aponte; J Vidal; M Tanner; H Mshinda; P Alonso
Journal:  Lancet       Date:  2001-05-12       Impact factor: 79.321

4.  Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.

Authors:  Daniel Chandramohan; Seth Owusu-Agyei; Ilona Carneiro; Timothy Awine; Kwame Amponsa-Achiano; Nathan Mensah; Shabbar Jaffar; Rita Baiden; Abraham Hodgson; Fred Binka; Brian Greenwood
Journal:  BMJ       Date:  2005-10-01

Review 5.  [Molecular markers of Plasmodium falciparum drug resistance].

Authors:  E C Eboumbou Moukoko; H Bogreau; S Briolant; B Pradines; C Rogier
Journal:  Med Trop (Mars)       Date:  2009-12

6.  Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial.

Authors:  Martin P Grobusch; Bertrand Lell; Norbert G Schwarz; Julian Gabor; Jenny Dornemann; Marc Potschke; Sunny Oyakhirome; Georg C Kiessling; Magdalena Necek; Matthias U Langin; Peter Klein Klouwenberg; Anna Klopfer; Benjamin Naumann; Handan Altun; Selidji T Agnandji; Julia Goesch; Marieluise Decker; Carmen L Ospina Salazar; Christian Supan; Davy U Kombila; Lea Borchert; Kai B Koster; Peter Pongratz; Akim A Adegnika; Isabelle von Glasenapp; Saadou Issifou; Peter G Kremsner
Journal:  J Infect Dis       Date:  2007-10-25       Impact factor: 5.226

7.  Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa.

Authors:  C V Plowe; A Djimde; M Bouare; O Doumbo; T E Wellems
Journal:  Am J Trop Med Hyg       Date:  1995-06       Impact factor: 2.345

8.  Rapid increase in the prevalence of sulfadoxine-pyrimethamine resistance among Plasmodium falciparum isolated from pregnant women in Ghana.

Authors:  Frank P Mockenhaupt; George Bedu-Addo; Teunis A Eggelte; Lena Hommerich; Ville Holmberg; Christa von Oertzen; Ulrich Bienzle
Journal:  J Infect Dis       Date:  2008-11-15       Impact factor: 5.226

9.  Potential impact of intermittent preventive treatment (IPT) on spread of drug-resistant malaria.

Authors:  Wendy Prudhomme O'Meara; David L Smith; F Ellis McKenzie
Journal:  PLoS Med       Date:  2006-04-04       Impact factor: 11.069

Review 10.  A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria.

Authors:  Stéphane Picot; Piero Olliaro; Frédérique de Monbrison; Anne-Lise Bienvenu; Ric N Price; Pascal Ringwald
Journal:  Malar J       Date:  2009-05-04       Impact factor: 2.979

View more
  18 in total

1.  Effects of extracts from Echinacea purpurea (L) MOENCH on mice infected with different strains of Toxoplasma gondii.

Authors:  Arquimedes Gasparotto Junior; Maria Luiza Antonio Cosmo; Michelle de Paula Reis; Pamela Secundo Dos Santos; Daniela Dib Gonçalves; Francielly Mourão Gasparotto; Italmar Teodorico Navarro; Emerson Luiz Botelho Lourenço
Journal:  Parasitol Res       Date:  2016-06-09       Impact factor: 2.289

2.  Molecular docking to Toxoplasma gondii thymidylate synthase-dihydrofolate reductase and efficacy of raltitrexed in infected mice.

Authors:  Michelle de Paula Reis; Daniely Alves de Lima; Karoline Bach Pauli; Carlos Eduardo Linhares Andreotti; André Luiz Soares de Moraes; Daniela Dib Gonçalves; Italmar Teodorico Navarro; Paulo Sérgio Alves Bueno; Flavio Augusto Vicente Seixas; Arquimedes Gasparotto Junior; Emerson Luiz Botelho Lourenço
Journal:  Parasitol Res       Date:  2018-03-17       Impact factor: 2.289

3.  Surveillance of molecular markers of Plasmodium falciparum resistance to sulphadoxine-pyrimethamine 5 years after the change of malaria treatment policy in Ghana.

Authors:  Nancy O Duah; Neils B Quashie; Benjamin K Abuaku; Peter J Sebeny; Karl C Kronmann; Kwadwo A Koram
Journal:  Am J Trop Med Hyg       Date:  2012-10-08       Impact factor: 2.345

Review 4.  Monitoring antifolate resistance in intermittent preventive therapy for malaria.

Authors:  Meera Venkatesan; Michael Alifrangis; Cally Roper; Christopher V Plowe
Journal:  Trends Parasitol       Date:  2013-08-12

5.  Prevalence of molecular markers of Plasmodium falciparum drug resistance in Dakar, Senegal.

Authors:  Nathalie Wurtz; Bécaye Fall; Aurélie Pascual; Silmane Diawara; Kowry Sow; Eric Baret; Bakary Diatta; Khadidiatou B Fall; Pape S Mbaye; Fatou Fall; Yaya Diémé; Christophe Rogier; Raymond Bercion; Sébastien Briolant; Boubacar Wade; Bruno Pradines
Journal:  Malar J       Date:  2012-06-13       Impact factor: 2.979

6.  Plasmodium falciparum susceptibility to anti-malarial drugs in Dakar, Senegal, in 2010: an ex vivo and drug resistance molecular markers study.

Authors:  Bécaye Fall; Aurélie Pascual; Fatoumata D Sarr; Nathalie Wurtz; Vincent Richard; Eric Baret; Yaya Diémé; Sébastien Briolant; Raymond Bercion; Boubacar Wade; Adama Tall; Bruno Pradines
Journal:  Malar J       Date:  2013-03-20       Impact factor: 2.979

7.  Prevalence of molecular markers of drug resistance in an area of seasonal malaria chemoprevention in children in Senegal.

Authors:  Aminata C Lo; Babacar Faye; El-Hadj Ba; Badara Cisse; Roger Tine; Annie Abiola; Magatte Ndiaye; Jean L A Ndiaye; Daouda Ndiaye; Cheikh Sokhna; Jules F Gomis; Yemou Dieng; Omar Faye; Omar Ndir; Paul Milligan; Matthew Cairns; Rachel Hallett; Colin Sutherland; Oumar Gaye
Journal:  Malar J       Date:  2013-04-23       Impact factor: 2.979

8.  Potential Impact of Seasonal Malaria Chemoprevention on the Acquisition of Antibodies Against Glutamate-Rich Protein and Apical Membrane Antigen 1 in Children Living in Southern Senegal.

Authors:  Magatte Ndiaye; Khadime Sylla; Doudou Sow; Roger Tine; Babacar Faye; Jean Louis Ndiaye; Yemou Dieng; Aminata Collé Lo; Annie Abiola; Badara Cisse; Daouda Ndiaye; Michael Theisen; Oumar Gaye; Michael Alifrangis
Journal:  Am J Trop Med Hyg       Date:  2015-08-17       Impact factor: 2.345

9.  RDTs as a source of DNA to study Plasmodium falciparum drug resistance in isolates from Senegal and the Comoros Islands.

Authors:  Nasserdine Papa Mze; Yaye Die Ndiaye; Cyrille K Diedhiou; Silai Rahamatou; Baba Dieye; Rachel F Daniels; Elizabeth J Hamilton; Mouhamadou Diallo; Amy K Bei; Dyann F Wirth; Souleymane Mboup; Sarah K Volkman; Ambroise D Ahouidi; Daouda Ndiaye
Journal:  Malar J       Date:  2015-09-29       Impact factor: 2.979

10.  Selection of antimalarial drug resistance after intermittent preventive treatment of infants and children (IPTi/c) in Senegal.

Authors:  Magatte Ndiaye; Roger Tine; Babacar Faye; Jean Louis Ndiaye; Ami Colle Lo; Khadime Sylla; Annie Abiola; Yémou Dieng; Daouda Ndiaye; Rachel Hallett; Oumar Gaye; Michael Alifrangis
Journal:  Am J Trop Med Hyg       Date:  2013-04-15       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.